• Explore /
  • Poster
  • / A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (n-pac) combined with OGX-427 (apatorsen) or placebo in patients (pts) with metastatic pancreatic cancer (mPaCa): The Rainier Trial.

A randomized, double-blinded, placebo-controlled phase II trial of gemcitabine (gem) plus nab-paclitaxel (n-pac) combined with OGX-427 (apatorsen) or placebo in patients (pts) with metastatic pancreatic cancer (mPaCa): The Rainier Trial.

Abstract Poster

Authors

null

Johanna C. Bendell

Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

Johanna C. Bendell , James D. Peyton , Scott Ryan Sommers , Henry Q. Xiong , Edward J. Crane , William N. Harwin , Mark Kozloff , Dianna Shipley , Dana Shelton Thompson , Mark Womack , Suzanne Fields Jones , Andrew H. Ko

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer

Clinical Trial Registration Number

NCT01844817

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4163)

DOI

10.1200/jco.2014.32.15_suppl.tps4163

Abstract #

TPS4163

Poster Bd #

240B

Abstract Disclosures

Similar Posters

First Author: Andrew H. Ko

First Author: David R. Spigel

First Author: Bradley Corr

First Author: Kim Anna Reiss